Investment Report

Stonegate Capital Partners’ Investment Report on BioMark Diagnostics

early stage cancer detection - BioMark Diagnostics we believe cancer can be cured
early stage cancer detection - BioMark Diagnostics we believe cancer can be cured

Prepared By

Stonegate Capital Partners

August 18, 2021
Marco Rodriguez, CFA
Stonegate Capital Partners

BioMark Diagnostics (CSE: BUX, OTCMKTS: BMKDF) is a Canadian Based company that develops proprietary, non-invasive, and accurate biotechnology and machine learning diagnostics solutions to detect early stage hard to detect and treat cancers. The company’s cancer diagnostics technology is a metabolomics-liquid biopsy based diagnostic assay that allows for cancer detection, monitoring, and prognosis for treatment for cancer in its early stages, where approximately 90% of which can be cured. The company is currently focused on commercialization of its cancer diagnostic assay and detection systems and hopes to start distribution once clinical trials are completed and regulatory acceptance is obtained within the next 12-18 months.

stonegate capital partners investment report biomark diagnostics

Exchange/Symbol

Price (CAD)

Market Cap (CAD mm)

Enterprise Value (CAD mm)

Shares Outstanding (mm)

Float (%)

Volument (3 mo avg)

52-week Range (CAD)

Industry

CNSX: BUX

$0.22

$10.4

$9.9

78.0

37.7%

82,463

$0.07-$0.63

Biotechnology

Sign up for the latest Biomark news

No paperwork, no hassle. We keep things digital, easy and regular.

*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.

early stage cancer detection - BioMark Diagnostics we believe cancer can be cured
early stage cancer detection - BioMark Diagnostics we believe cancer can be cured